How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative biologic medicines for serious diseases. With a market capitalization of approximately $233.8 billion, the company focuses on oncology, inflammation, general medicine, and rare diseases, leveraging human genetics and advanced biologics manufacturing to improve patient outcomes globally.

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and AMGN fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and dominance within the general drug manufacturers industry. Amgen stands out for its strong portfolio of innovative therapies, including Repatha, Prolia, and Enbrel, alongside a growing oncology pipeline. Its exceptional profitability, product-sales growth, and international expansion demonstrate strong demand, operational efficiency, and potential for continued growth.